These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37438617)

  • 21. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
    Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
    Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discontinuation of denosumab in men with prostate cancer.
    Sølling AS; Harsløf T; Brockstedt HK; Langdahl B
    Osteoporos Int; 2023 Feb; 34(2):291-297. PubMed ID: 36402867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
    Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
    Borek DM; Smith RC; Gruber CN; Gruber BL
    Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
    Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
    Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple vertebral fractures following discontinuation of denosumab treatment: Ten clinical cases report.
    Fernández Fernández E; Benavent Núñez D; Bonilla Hernán G; Monjo Henry I; García Carazo S; Bernad Pineda M; Balsa Criado A; Aguado Acín P
    Reumatol Clin (Engl Ed); 2020; 16(6):480-484. PubMed ID: 30846260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
    Hong N; Shin S; Lee S; Kim KJ; Rhee Y
    Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys.
    Haider IT; Sawatsky A; Zhu Y; Page R; Kostenuik PJ; Boyd SK; Edwards WB
    Bone; 2022 Nov; 164():116517. PubMed ID: 35961611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.
    De Vincentis S; Domenici D; Ansaloni A; Boselli G; D'Angelo G; Russo A; Taliani E; Rochira V; Simoni M; Madeo B
    J Endocrinol Invest; 2022 Oct; 45(10):1887-1897. PubMed ID: 35590044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study.
    Jeong C; Lee J; Kim J; Ha J; Jo K; Lim Y; Kim MK; Kwon HS; Sohn TS; Song KH; Kang MI; Baek KH
    Endocrinol Metab (Seoul); 2023 Apr; 38(2):260-268. PubMed ID: 37150519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
    Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
    Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis.
    Zeytinoglu M; Naaman SC; Dickens LT
    Endocrinol Metab Clin North Am; 2021 Jun; 50(2):205-222. PubMed ID: 34023039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic.
    Kocijan R; Stockinger T; Haschka J; Reichardt B; Resch H; Zwerina J; Behanova M
    Bone; 2022 Sep; 162():116477. PubMed ID: 35779846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P
    Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
    Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
    Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.